Young TIL / National Cancer Institute - LARVOL DELTA

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=85 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2025 ➔ Oct 2027 | Trial primary completion date: Oct 2025 ➔ Oct 2027

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... (clinicaltrials.gov) - P2 | N=102 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jun 2026 ➔ Sep 2024 | Trial primary completion date: Jun 2025 ➔ Sep 2024

Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (clinicaltrials.gov) - P2 | N=170 | Recruiting | Sponsor: National Cancer Institute (NCI) | N=20 ➔ 170 | Trial completion date: Jun 2026 ➔ Jun 2029 | Trial primary completion date: Jun 2025 ➔ Jun 2028 | Suspended ➔ Recruiting

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer (clinicaltrials.gov) - P2 | N=332 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2024 ➔ Dec 2029 | Trial primary completion date: Dec 2024 ➔ Dec 2028

Trial completion date • Trial primary completion date • Brain Cancer • Breast Cancer • Colorectal Cancer • Endocrine Cancer • Endometrial Cancer • Glioblastoma • Hepatocellular Cancer • Hepatology • Neuroendocrine Tumor • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=85 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial primary completion date: Oct 2024 ➔ Oct 2025

Metastases • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... (clinicaltrials.gov) - P2 | N=102 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: Jun 2024 ➔ Jun 2025

Metastases • Trial completion date • Trial primary completion date • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer (clinicaltrials.gov) - P2 | N=332 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial primary completion date: Dec 2023 ➔ Dec 2024

Metastases • Trial primary completion date • Breast Cancer • Colorectal Cancer • Endocrine Cancer • Gastrointestinal Cancer • Glioblastoma • Hepatocellular Cancer • Hepatology • Neuroendocrine Tumor • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (clinicaltrials.gov) - P2 | N=20 | Suspended | Sponsor: National Cancer Institute (NCI) | N=170 ➔ 20 | Recruiting ➔ Suspended

Enrollment change • Metastases • Trial suspension • Melanoma • Oncology • Solid Tumor

Development of a production process to generate CD8+ T cell-enriched tumor infiltrating lymphocyte (TIL) products with increased cytotoxic potential for the treatment of patients with solid cancers. (ESMO-IO 2022) - "The standard 'young TIL' production process using high dose IL-2 and OKT-3 was used as a standard comparison...Conclusions This study shows that CD8 cis-targeted IL-2 can be used to generate TIL products mainly comprising CD8+ T cells, thereby potentially improving cytotoxic potential and therapeutic efficacy. The use of CD3/28 TransAct, compared to anti-CD3 stimulation (OKT-3) improved the final yield of CD8+ T cells in the TIL products."

Clinical • Cervical Cancer • Endometrial Cancer • Melanoma • Oncology • Solid Tumor • CD8

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (clinicaltrials.gov) - P2 | N=33 | Completed | Sponsor: National Cancer Institute (NCI) | Trial primary completion date: Jul 2022 ➔ Oct 2021

Trial primary completion date • Melanoma • Oncology • Solid Tumor

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes (clinicaltrials.gov) - P1 | N=6 | Terminated | Sponsor: Yale University | N=30 ➔ 6 | Active, not recruiting ➔ Terminated; lack of funds

Enrollment change • Trial termination • Melanoma • Oncology • Solid Tumor • IL2 • PD-L1

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (clinicaltrials.gov) - P2 | N=33 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Sep 2029 ➔ Jul 2022 | Trial primary completion date: Oct 2028 ➔ Jul 2022

Trial completion • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor